WuXi Biologics releases 2023 ESG report to demonstrate Investing.com’s strong commitment to sustainable development



  • The Company is deeply committed to working with clients around the world to achieve ESG success and create long-term value for all stakeholders.
  • The company has made significant progress in combating climate change, achieving a 29% reduction in 2023 Scope 1 and 2 greenhouse gas emissions intensity since 2020.
  • The company achieved its initial goal of reducing water intensity by 18% and increased it to 30% by 2025.
  • The company has more than 12,000 employees from 56 countries, with 53% of STEM (science, technology, engineering, math) positions held by women.
  • The company is rated an ESG industry leader by major ESG rating agencies.

Hongkong, April 29, 2024 /PRNewswire/—— WuXi Biologics (Hongkong:) (“WuXi Biologics”) (2269.HK), the world's leading contract research, development and manufacturing organization (CRDMO), today Released the 2023 Environmental, Social and Governance (ESG) Report, emphasizing the company’s substantial progress in promoting sustainable development.

WuXi Biologics ESG strategies are consistently aligned with the company’s vision and mission and integrated into its global operations. In 2023, the company will join United Nations (United Nations) Global Compact, demonstrating its commitment to sustainable development. In 2023, its significant ESG progress was recognized by major ESG rating agencies for its progress in delivering on its commitments. The company is included in the S&P Dow Jones Sustainability™ World Index and the Emerging Markets Index; awarded “AAA” Rated by MSCI ESG Ratings; awarded Platinum Medal of Excellence eco-vadis; Is considered to be Excellent enterprises in industry and region By Sustainalytics; Selected to CDP Water Security “A List”; and received CDP Climate Change Score “A-“.

“As a participant United Nations Global Compactthe world’s largest corporate sustainability initiative, WuXi Biologics It regards sustainable development as the cornerstone of its business development strategy. Dr. Chris ChanCEO and Chairman of the ESG Committee WuXi Biologics. “2023 will be a year of both opportunities and challenges for the industry. WuXi Biologics We maintain sustainable growth momentum through our unique CRDMO business model. We are deeply committed to our shared responsibility to support positive social and environmental impacts across the entire value chain with our customers around the world.

In this year's ESG report, the company provides a transparent and comprehensive update on its ESG strategy and progress on major initiatives that impact its employees, global partners, communities and the environment.

Strengthen corporate governance

Guided by its ESG strategy, WuXi Biologics A strong governance mechanism has been established, including the supervision of the ESG Committee of the Board of Directors and the guidance of the Company’s Board of Directors ESG Steering Group, and efficient implementation of major ESG issues by a dedicated ESG department and cross-functional working group. It has a zero-tolerance policy for unethical behavior and is committed to the highest standards of integrity and business ethics. 2023, Ethics and Compliance Committee Establish a compliance management organization as the highest compliance management organization to enhance the ability to prevent and respond to compliance risks. In accordance with the United Nations Sustainable Development Goals, the company remains committed to a science-based and measurable ESG goal matrix, and subsequently developed a comprehensive roadmap while tracking the progress of continuous improvement.

Coping with climate change

For businesses around the world, achieving and maintaining environmental sustainability has become an important part of long-term sustainability. 2023, WuXi Biologics Commitment to the Science-Based Targets Initiative (SBTi) marks a new milestone in its journey to net zero. The company has made meaningful progress in combating climate change and reducing carbon emissions. The company has achieved a 29% reduction in scope 1 and scope 2 greenhouse gas emissions intensity in 2023 since the 2020 base year. WuXi Biologics Achieve the goal of reducing water intensity ahead of schedule, and proactively raise the goal of reducing water intensity from 18% to 30% in 2025 from the base year of 2019.

Promote sustainable value chains

WuXi Biologics Significant efforts are made to maintain transparent dialogue and build strong connections with all stakeholders. The company is committed to working with supply chain business partners who operate in compliance with its ethical standards and principles, and strives to integrate environmental and social sustainability into the company's supplier management system. WuXi Biologics Engage and engage with suppliers through access screening, regular assessments and audits, and ongoing training to drive best practice and positively impact their value chain.

Promote diversity, equity and inclusion

WuXi Biologics The success of a business is due to its employees. WuXi Biologics With more than 12,000 employees, they are highly dedicated and experienced professionals representing 56 nationalities and diverse backgrounds. In 2023, the company established a Diversity, Equity and Inclusion (DEI) Committee composed of employees from different departments and countries to formulate and oversee the implementation of DEI strategies. The company encourages women to pursue careers in science, technology, engineering and mathematics (STEM) fields. Currently, 53% of STEM positions are held by female employees, far exceeding the industry average.

Practice corporate social responsibility

WuXi Biologics Consider community involvement an important social responsibility. In 2023, employees volunteered more than 8,000 hours. Applying core competencies to benefit patients around the world is one of the company's three pillars of corporate social responsibility. As part of its business, the company works closely with customers around the world to bring new treatments to patients with rare diseases. There are currently 19 ongoing rare disease projects on the company's comprehensive platform. In 2023, the company has approved an innovative Pompeii therapy in the EU, U.K. and us To celebrate this milestone, the company launched a “Health Run” charity event to raise scholarships for students with rare diseases. The program is supported by more than 1,500 employee volunteers from 10 locations around the world.

End-to-end green CRDMO solution

In order to promote the environmental transformation of the biopharmaceutical industry, WuXi Biologics The company integrates ESG concepts into multiple innovative technology platforms such as WuXiBody™, WuXiUP™, and WuXiUI™ to provide end-to-end green CRDMO solutions for global customers. The company also leveraged lean management processes to complete more than 150 Kaizen projects that resulted in environmental and economic outcomes, including improved operational efficiency and reduced resource consumption.

“We are proud of the concrete progress we have made towards achieving our ESG goals. More importantly, these efforts have delivered substantial benefits to the broader communities in which we operate,” commented Dr. Chen. “As we pursue our 2024 goals with courage and determination, WuXi Biologics We will continue to embed sustainability into the core commitment that has always defined what we do: enabling our global customers to bring life-changing treatments to patients around the world.

For the complete 2023 ESG report, please visit: https://www.wuxibiologics.com/sustainability/

about WuXi Biologics

WuXi Biologics (Stock code: 2269.HK) is the world’s leading contract research, development and manufacturing organization (CRDMO) provides end-to-end solutions that enable partners to discover, develop and manufacture biologics “from concept to commercialization” to benefit patients around the world.

With more than 12,000 skilled employees China, USA, Ireland, Germany and Singapore, WuXi Biologics Leverages its technology and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.as December 31, 2023, WuXi Biologics 698 integrated customer projects are being supported, 24 of which are commercial manufacturing.

WuXi Biologics Considering environmental, social and governance (ESG) responsibility as an integral part of our ethos and business strategy, we aim to be the ESG leader in the biologics CRDMO space. Our facilities use next-generation biomanufacturing technology and clean energy. We have also established an ESG Committee led by our CEO to guide a comprehensive ESG strategy and its implementation to enhance our commitment to sustainable development.

For more information WuXi Biologicsplease visit: Wuxi Biological Products Network.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *